Abstract:The Hedgehog (Hh) signaling pathway plays a critical role in controlling patterning, growth and cell migration during embryonic development. Aberrant activation of Hh signaling has been linked to tumorigenesis in various cancers, such as basal cell carcinoma (BCC) and medulloblastoma. As a key member of the Hh pathway, the Smoothened (Smo) receptor, a member of the G protein-coupled receptor (GPCR) family, has emerged as an attractive therapeutic target for the treatment and prevention of human cancers. The recent determination of several crystal structures of Smo in complex with different antagonists offers the possibility to perform structure-based virtual screening for discovering potent Smo antagonists with distinct chemical scaffolds. In this study, based on the two Smo crystal complexes with the best capacity to distinguish the known Smo antagonists from decoys, the molecular docking-based virtual screening was conducted to identify promising Smo antagonists from ChemDiv library. A total of 21 structurally novel and diverse compounds were selected for experimental testing, and six of them exhibited significant inhibitory activity against the Hh pathway activation (IC50 < 10 μM) in a GRE (Gli-responsive element) reporter gene assay. Specifically, the most potent compound (compound 20: 47 nM) showed comparable Hh signaling inhibition to vismodegib (46 nM). Compound 20 was further confirmed to be a potent Smo antagonist in a fluorescence based competitive binding assay. Optimization using substructure searching method led to the discovery of 12 analogues of compound 20 with decent Hh pathway inhibition activity, including four compounds with IC50 lower than 1 μM. The important residues uncovered by binding free energy calculation (MM/GBSA) and binding free energy decomposition were highlighted and discussed. These findings suggest that the novel scaffold afforded by compound 20 can be used as a good starting point for further modification/optimization and the clarified interaction patterns may also guide us to find more potent Smo antagonists.

Strategies to target the Hedgehog signaling pathway for cancer therapy

Current Status of Hedgehog Signaling Inhibitors

Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance

Progress in research of novel anticancer drugs targeting Hedgehog signaling pathway

Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy

Hedgehog Inhibitors: a Patent Review (2013 – Present)

Novel-smoothened Inhibitors for Therapeutic Targeting of Naïve and Drug-Resistant Hedgehog Pathway-Driven Cancers.

Hedgehog Signaling: from Basic Biology to Cancer Therapy

Discovery of a Potent Hedgehog Pathway Inhibitor Capable of Activating Caspase8-Dependent Apoptosis.

Unveiling the role of the Hedgehog signaling pathway in chronic liver disease: Therapeutic insights and strategies

Hedgehog Signaling Pathway and Autophagy in Cancer

A Novel Hedgehog Inhibitor for the Treatment of Hematological Malignancies

Hedgehog Signaling in Tissue Homeostasis, Cancers, and Targeted Therapies.

Molecular pathways: the role of primary cilia in cancer progression and therapeutics with a focus on Hedgehog signaling

Hedgehog Pathway Blockade Inhibits Melanoma Cell Growth in Vitro and in Vivo

Hedgehog signaling controls cytotoxic T cell migration in the tumour microenvironment.

Progress in Research on Small Molecular Inhibitors of Hedgehog Signal Pathway

Scaffold Hopping Approach to a New Series of Smoothened Antagonists

Beyond cyclopamine: Targeting Hedgehog signaling for cancer intervention

Discovery of Potent and Novel Smoothened Antagonists Via Structure-Based Virtual Screening and Biological Assays.

Targeting Super-Enhancer-Driven Transcriptional Dependencies Suppresses Aberrant Hedgehog Pathway Activation and Overcomes Smoothened Inhibitor Resistance